Skip to content

NASDAQ · mid · thesis board

CRSP CRISPR Therapeutics

CRISPR/Cas9 ex vivo and in vivo editing

View race

Thesis

Editorial summary — not a primary filing

Casgevy commercial ramp plus in vivo editing pipeline (CTX310 and beyond).

Next gate

2026-09-01Company-guidedlabel expand

Commercial / access update

19 days · Company: Company guidance

Survive-to-Event

ok

Cash covers the next gate with ~32 months spare (curated estimate).

Unverified estimate — not from a live SEC parse

Cash runway (~995d)100%
Days to gate (19d)2%
Show math

$1.8B cash ÷ $55M/mo burn ≈ 995 days. Source: curated SEC quarter figures.

Cash $1.8B as of 2026-03-31 (SEC)

Pipeline spine

  1. Preclinical
  2. Ph1
  3. Ph2
  4. Ph3
  5. Filed
  6. Approved
Secondary assets (1)
  • CTX310 in vivo · Ph1 · gene-editing-rare

Rivals in this race

Open race →
BLUEApprovedokEDITPh2okBEAMPh1ok

Risks

  • Commercial uptake
  • In vivo delivery risk
  • Competition from Beam/Intellia
  • Pricing

Source trail

  1. SECCash from latest reported quarter (curated)as of 2026-03-31
  2. ClinicalTrials.govNCT03745287as of 2026-07-01
  3. CompanyIR / press disclosuresas of 2026-07-01